Parathyroidectomy in a patient treated with emicizumab
| 23 déc. 2019
Publié en ligne: 23 déc. 2019
Pages: 51 - 53
© 2019 Helen Hupston, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
A patient with haemophilia A and inhibitors undergoing parathyroidectomy continued a standard maintenance dose of emicizumab, with bleed risk managed intra- and postoperatively with recombinant Factor VIIa (rFVIIa) and tranexamic acid. Despite the risk of hypercoagulability with the combination of emicizumab and rFVIIa, no postoperative complications were reported.© Shutterstock